This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Repros Therapeutics Corporate Update

  • Enrollment in 6 Month Open Label Study Near Completion
  • FDA Meeting Request Submitted
  • Joachim F. Wernicke, Ph.D, M.D., Named Chief Medical Officer
  • Company to Present at BIO CEO in NYC February 11, 2013

THE WOODLANDS, Texas, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided an update for both of its core clinical programs. 

Androxal ® Six Month Open Label Study (ZA-300)

As part of the FDA requirement for total number of subjects to be exposed for six months, the Company is conducting a 500 subject open label study. To date, the Company has enrolled 499 subjects and expects the study to be fully enrolled this week.

Androxal ® Pivotal Studies (ZA-301 and ZA-302)

The Company has sent a "request for guidance" letter to the FDA. The key points were:
  • The identification of a single high enrolling site with a population whose baseline characteristics appear different from the other sites;
  • The Company has proposed enrolling an additional 40 subjects into each of the two pivotal studies to allow for subset analysis while retaining the power of the original protocols;
  • The Company proposed moving two sites from the enrolling study ZA-302 to the closed for enrollment study ZA-301.

When the company receives guidance from FDA, it will update the financial community.

Proellex ®-V

The Company has requested an end of Phase 2 meeting for its vaginal Proellex program for the treatment of uterine fibroids. The request was for a meeting before the end of April 2013.

Joachim F. Wernicke, Ph.D., M.D. named Chief Medical Officer

As part of the Company's endeavors to expand its clinical and regulatory capabilities, Repros has hired Dr. Wernicke as Chief Medical Officer ("CMO"), effective February 5, 2013. Dr. Wernicke joined Eli Lilly and Company ("Lilly") in 1984 and was involved with clinical development and regulatory matters related to Prozac and other central nervous system drugs until 1990. Between 1990 and 1995, he was the VP of Clinical and Regulatory Affairs for Cyberonics, Inc. Thereafter, between 1995 and 1999, he served as a consultant for various pharmaceutical, biotechnology, and medical device companies. In 1999, he rejoined Lilly and was involved in the development and approval of Strattera and Cymbalta. In 2004, he joined the Global Patient Safety group of Lilly and at various times was responsible for Cymbalta, Strattera, Zyprexa, Symbyax, and Effient. He retired from Lilly in 2012.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
TSLA $212.97 -4.30%
YHOO $37.05 2.90%
AAPL $93.13 -0.52%
FB $118.02 -0.03%
GOOG $698.38 0.39%


Chart of I:DJI
DOW 17,700.50 +49.24 0.28%
S&P 500 2,055.36 +4.24 0.21%
NASDAQ 4,731.3310 +5.6920 0.12%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs